Knowledge Center

Article / Jul 27, 2015

Hovione and Invion sign development agreement for first inhaled non-steroidal anti-inflammatory for asthma

Authors:
Source:
Manufacturing Chemist, 27 July 2015

Portuguese API manufacturer Hovione has agreed with Invion to progress the development of inhaled INV104 (zafirlukast) as a potential new treatment for asthma.

Hovione and the Australian drug developer will collaborate to develop the proprietary novel technology – a dry powder formulation of the compound INV104 (zafirlukast) delivered by Hovione’s inhaler.

Related links

Read article here

Also in the Knowledge Center

Related Content

Customers

Full transparency for your project anywhere at any time.

Page
Read more

Hot melt extrusion

Hot melt extrusion is a fast growing technology platform thas is utilized to solve difficult formulation challenges, primarily in the area of solubilization.

Page
Read more

Hovione expands nasal drug delivery capabilities with the development of nasal powder delivery device technology in collaboration with IDC

Press Release / Nov 29, 2023
Article
View